Mainstreaming Precision Oncology: Transforming Care Through Science, Medicine and Equity.

APOS 26 is designed for Australian oncology professionals, including clinicians, researchers, pathologists, and leaders from the life sciences, advocacy, and policy sectors.

We are delighted to announce our first international speaker:

Dr. Vivek Subbiah, Medical Oncologist and Chief of Early Phase Drug Development, Sarah Cannon Research Institute (Nashville, TN). Dr. Subbiah brings deep expertise in tumour-agnostic therapies and the global future of precision oncology. He has led more than 100 early-phase trials and co-authored over 350 peer-reviewed publications in journals including NEJM, Nature Medicine, and JCO.

Sponsorship opportunities are now available — align your organisation with this key precision oncology event and connect with a highly engaged professional audience.